The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
复制标题
DOI：
10.29252/.23.1.68
复制
发表时间：
2019-01
影响因子：
--
通讯作者：
Alizadeh Sani M
中科院分区：
文献类型：
--
作者：
Khalili L;Alipour B;Asghari Jafar-Abadi M;Faraji I;Hassanalilou T;Mesgari Abbasi M;Vaghef-Mehrabany E;Alizadeh Sani M
2型糖尿病（T2 DM）与肠道微生物群有关，具有许多分子机制。通过益生菌调节肠道微生物群可以有效治疗T2 DM。本试验的目的是评估干酪乳杆菌对2型糖尿病患者血糖控制和血清sirtuin 1（SIRT 1）和胎球蛋白A的影响。将40例T2 DM患者（每组n = 20）分为干预组（益生菌）和安慰剂组。干预组每天服用一粒含108 cfu L.八周的时间。安慰剂组服用含麦芽糊精的胶囊，持续相同时间。采集人体测量、饮食摄入问卷和血液样本，并在试验开始和结束时由内分泌学家对患者进行评估。与安慰剂组相比，益生菌组的空腹血糖、胰岛素浓度和胰岛素抵抗显著降低（分别为-28.32 [-50.23 to -6.41]，0.013; -3.12 [-5.90 to -0.35]，0.028; -32.31 [-55.09 to -9.54]，0.007）。此外，干预后HbA 1c降低，但降低不显著（-0.45 [-0.96至0.05]，0.077）。与安慰剂相比，L.在试验结束时，补充干酪素显著增加SIRT 1和降低胎球蛋白-A水平（分别为0.52 [0.026至1.02]，0.040; -17.56 [-32.54至-2.58]，0.023）。L.补充干酪素影响SIRT 1和胎球蛋白-A水平，从而改善T2 DM受试者的血糖反应。影响SIRT 1和胎球蛋白-A水平引入了糖尿病管理中益生菌作用的新已知机制。
Type 2 diabetes mellitus (T2DM) is related to the gut microbiota with numerous molecular mechanisms. Modulating the gut microbiota by probiotics could be effective in management of T2DM. The aim of the present trial was to evaluate the effect of Lactobacillus casei on glycemic control and serum sirtuin1 (SIRT1) and fetuin-A in patients with T2DM. Forty patients with T2DM (n = 20 for each group) were divided into intervention (probiotic) and placebo groups. The intervention group received a daily capsule containing 108 cfu of L. casei for eight weeks. The patients in placebo group took capsules containing maltodextrin for the same time duration. Anthropometric measurements, dietary intake questionnaires, and blood samples were collected, and the patients were assessed by an endocrinologist at the beginning and at the end of the trial. Fasting blood sugar, insulin concentration, and insulin resistance significantly decreased in probiotic group compared with placebo group (-28.32 [-50.23 to -6.41], 0.013; -3.12 [-5.90 to -0.35], 0.028; -32.31 [-55.09 to -9.54], 0.007, respectively). Moreover, HbA1c reduced after intervention, but the reduction was not significant (-0.45 [-0.96 to 0.05], 0.077). In comparison with placebo, the L. casei supplementation significantly increased SIRT1 and decreased fetuin-A levels at the end of the trial (0.52 [0.026 to 1.02], 0.040; -17.56 [-32.54 to -2.58], 0.023, respectively). L. casei supplementation affected SIRT1 and fetuin-A levels in a way that improved glycemic response in subjects with T2DM. Affecting the SIRT1 and fetuin-A levels introduces a new known mechanism of probiotic action in diabetes management.